Stocktoria
Nasus Pharma Ltd NSRX
Nasus Pharma Ltd financials (annual)
Bars are annual figures from 2024 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.2B | — |
| R&D expense | $2.2M | $335,000 |
| Operating income | -$4.9M | -$1.1M |
| Net income | -$5.9M | -$1.5M |
| EPS (diluted) | $-0.72 | $-0.22 |
| Operating cash flow | -$4.9M | -$665,000 |
| Free cash flow | -$4.9M | — |
| Cash & equivalents | $1.2M | $284,000 |
| Total assets | $5.0M | $717,000 |
| Total liabilities | $2.2M | $3.9M |
| Shareholders' equity | $2.8M | -$3.2M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.